European Commission on Nostr: 🏭 The EU excels in innovative medicines but faces challenges: over 50% of medicine ...
🏭 The EU excels in innovative medicines but faces challenges: over 50% of medicine shortages are due to manufacturing issues and we also need to be vigilant about keeping generic drug production in Europe.
Our Critical Medicine Act aims to ensure:
💊 ensure that essential medicines are always available to EU patients, filling gaps where the market falls short
🇪🇺 boost local production
🧪 improve security of supply of key ingredients
= more stability for the EU's pharmaceutical industry.
Published at
2025-03-11 15:18:56Event JSON
{
"id": "64d96edeb7b5199fe73d68dcfc70bcf6008bfbe9a24c5c457d50e5e460706449",
"pubkey": "f5920dd6d8a53368029033bddc3c54a7a123e28ce639b96513bcc054e94097d9",
"created_at": 1741706336,
"kind": 1,
"tags": [
[
"imeta",
"url https://ec.social-network.europa.eu/system/media_attachments/files/114/144/463/282/404/066/original/46ac8a1cdbc23ef4.png",
"m image/png",
"dim 1080x1080",
"blurhash U8RfUj%L~U%M%2aeayoft5oIIVR-xuf6jsof"
],
[
"proxy",
"https://ec.social-network.europa.eu/users/EUCommission/statuses/114144466501129575",
"activitypub"
]
],
"content": "🏭 The EU excels in innovative medicines but faces challenges: over 50% of medicine shortages are due to manufacturing issues and we also need to be vigilant about keeping generic drug production in Europe.\n\nOur Critical Medicine Act aims to ensure:\n\n💊 ensure that essential medicines are always available to EU patients, filling gaps where the market falls short \n🇪🇺 boost local production\n🧪 improve security of supply of key ingredients\n\n= more stability for the EU's pharmaceutical industry.\n\nhttps://ec.social-network.europa.eu/system/media_attachments/files/114/144/463/282/404/066/original/46ac8a1cdbc23ef4.png",
"sig": "318eaca6ebf45f296986a773a741b141b5cf7111e3c57275979a20e35828f1ee6701606b1c7189e314611cc39d57b119a0bc1fd7f9e901d0b4aa1fc1bd4b8c35"
}
